Glucocorticoid Receptor Antagonist Testing for Cushing's Subtype Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Distinguishing between ACTH-dependent and ACTH-independent Cushing's syndrome is crucial for appropriate treatment, as current methods lack effective differential diagnosis, leading to potential delays and inappropriate treatment strategies.
Innovation Solution
Administering a glucocorticoid receptor antagonist (GRA) to patients with basal ACTH levels below 25 pg/mL, observing changes in ACTH and cortisol levels post-administration to differentiate between ACTH-dependent and ACTH-independent Cushing's syndrome, guiding targeted surgical interventions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used to distinguish between ACTH-Dependent and ACTH-Independent Cushing's syndrome, then diagnosis can be made, but the diagnostic accuracy and ability to guide surgical intervention is inadequate
Solution Approach 1:
The patent utilizes dynamic changes in ACTH and cortisol levels following GRA administration as diagnostic parameters. By measuring hormone levels at multiple time points (basal and post-administration) and calculating the ACTH:cortisol ratio, the method transforms static hormone level measurements into dynamic functional assessments, thereby improving diagnostic accuracy for distinguishing ACTH-Dependent from ACTH-Independent Cushing's syndrome
Solution Approach 2:
The glucocorticoid receptor antagonist (GRA) serves as an intermediary substance that temporarily disrupts the HPA axis to reveal underlying pathological patterns. By administering GRA and observing the subsequent hormonal response, the method uses this pharmacological mediator to amplify diagnostic information that cannot be obtained through baseline measurements alone
2Reliability
If surgical intervention is performed without accurate differential diagnosis, then treatment can be provided, but the appropriateness and effectiveness of surgical intervention cannot be ensured
Solution Approach 1:
The patent performs differential diagnosis through GRA administration and hormonal response assessment before committing to surgical intervention. This preliminary diagnostic action identifies the appropriate surgical target (pituitary vs. adrenal) and predicts treatment response, ensuring that surgical intervention is both appropriate and likely to be effective before time and resources are invested
Solution Approach 2:
The method incorporates feedback from the patient's hormonal response to GRA administration to guide treatment decisions. By measuring ACTH and cortisol levels post-administration and calculating the ACTH:cortisol ratio, the system provides feedback that confirms the diagnosis and guides the selection of appropriate surgical intervention, thereby ensuring treatment effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate differential diagnosis and tailored treatment approaches, reducing unnecessary delays and improving treatment efficacy by identifying the need for transsphenoidal surgery, ectopic tumor surgery, or adrenal surgery based on ACTH and cortisol level responses to GRA.
Implementation Method 1
Mifepristone binds to the GR with high affinity, with a dissociation constant (Kd) of 10-9 M
Data Source
AI summary
Methods for treating and differential diagnosis between ACTH-Dependent and ACTH-Independent Cushing's syndrome are disclosed, in which a glucocorticoid receptor antagonist (GRA) is administered to a Cushing's syndrome patient with a basal ACTH level less than about 25 pg/mL. If i) the patients blood ACTH and ii) the patients blood cortisol, or adrenal hormone, or adrenal pre-hormone levels rise, or if the ACTH:cortisol ratio increases, then ACTH-Dependent Cushing's syndrome is diagnosed. If those levels do not rise, or if the ACTH:cortisol ratio decreases, then ACTH-Independent Cushing's syndrome is diagnosed. In some instances, the patient is recovering from surgery to remove an ACTH secreting tumor, and the method described herein is used to determine if the tumor resection was successful or complete. The GRA may be mifepristone, or a non-steroidal GRA having a heteroaryl-ketone fused azadecalin backbone, an octahydro fused azadecalin backbone, a cyclohexyl pyrimidine backbone, or a fused azadecalin backbone.